KBC Group NV Purchases 56,580 Shares of LivaNova PLC (NASDAQ:LIVN)

KBC Group NV raised its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 130.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,928 shares of the company's stock after purchasing an additional 56,580 shares during the quarter. KBC Group NV owned 0.18% of LivaNova worth $4,628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Point72 Asset Management L.P. boosted its position in LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after buying an additional 806,374 shares during the period. Geode Capital Management LLC grew its position in LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock worth $70,676,000 after acquiring an additional 8,331 shares during the last quarter. Victory Capital Management Inc. increased its stake in LivaNova by 16.6% in the 3rd quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock worth $49,130,000 after purchasing an additional 133,401 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after purchasing an additional 25,277 shares during the period. Finally, Emerald Advisers LLC grew its holdings in shares of LivaNova by 2.1% in the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company's stock worth $36,542,000 after purchasing an additional 14,302 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Stock Down 3.8 %

Shares of NASDAQ:LIVN traded down $1.89 during trading on Monday, hitting $48.06. The stock had a trading volume of 390,847 shares, compared to its average volume of 480,750. The company has a market capitalization of $2.61 billion, a PE ratio of 114.43 and a beta of 1.01. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm's fifty day moving average is $49.00 and its 200 day moving average is $49.90. LivaNova PLC has a 12 month low of $43.15 and a 12 month high of $64.47.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on LIVN. StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, January 23rd. Needham & Company LLC reiterated a "buy" rating and set a $75.00 target price on shares of LivaNova in a report on Tuesday, January 28th. Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. Finally, Robert W. Baird upped their price target on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, LivaNova presently has a consensus rating of "Buy" and an average price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.